scispace - formally typeset
M

Mark B. Effron

Researcher at Eli Lilly and Company

Publications -  153
Citations -  8547

Mark B. Effron is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Percutaneous coronary intervention & Prasugrel. The author has an hindex of 38, co-authored 138 publications receiving 8032 citations. Previous affiliations of Mark B. Effron include Northwestern University & Durham University.

Papers
More filters
Journal Article

The effect of digoxin on mortality and morbidity in patients with heart failure

Gilbert J. Perry, +398 more
TL;DR: Digoxin did not reduce overall mortality, but it reduced the rate of hospitalization both overall and for worsening heart failure, which defines more precisely the role of digoxin in the management of chronic heart failure.
Journal ArticleDOI

Randomized, Placebo-Controlled Trial of Platelet Glycoprotein IIb/IIIa Blockade With Primary Angioplasty for Acute Myocardial Infarction

TL;DR: Patients with acute MI of <12 hours’ duration were randomized to placebo or abciximab if they were deemed candidates for primary PTCA, and the primary efficacy end point was death, reinfarction, or any (urgent or elective) target vessel revascularization (TVR) at 6 months by intention-to-treat (ITT) analysis.
Journal ArticleDOI

Mechanisms of blood flow during cardiopulmonary resuscitation.

TL;DR: It appears that pressure generation and blood flow during CPR in the dog result from a generalized rise in intrathoracic pressure, not from direct cardiac compression, which can dramatically increase carotid blood flow During CPR.
Journal ArticleDOI

Emergency Administration of Abciximab for Treatment of Patients With Acute Ischemic Stroke: Results of an International Phase III Trial Abciximab in Emergency Treatment of Stroke Trial (AbESTT-II)

TL;DR: This phase 3 trial did not demonstrate either safety or efficacy of intravenous administration of abciximab for the treatment of patients with acute ischemic stroke regardless of end point or population studied.